Evidence map›Paper›PMID 28750094›Full record

ArticlePloS one2017

Crystal structure and kinetic analysis of the class B3 di-zinc metallo-β-lactamase LRA-12 from an Alaskan soil metagenome.

María Margarita Rodríguez, Raphaël Herman, Barbara Ghiglione, Frédéric Kerff, Gabriela D'Amico González, Fabrice Bouillenne, Moreno Galleni, Jo Handelsman, Paulette Charlier, Gabriel Gutkind and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

María Margarita RodríguezCátedra de Microbiología, Departamento de Microbiología, Inmunología y Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Raphaël HermanInBioS, Centre d'Ingénierie des Protéines, Université de Liège, Liège, Belgium.
Barbara GhiglioneCátedra de Microbiología, Departamento de Microbiología, Inmunología y Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Frédéric KerffInBioS, Centre d'Ingénierie des Protéines, Université de Liège, Liège, Belgium.
Gabriela D'Amico GonzálezCátedra de Microbiología, Departamento de Microbiología, Inmunología y Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Fabrice BouillenneInBioS, Centre d'Ingénierie des Protéines, Université de Liège, Liège, Belgium.
Moreno GalleniInBioS, Centre d'Ingénierie des Protéines, Université de Liège, Liège, Belgium.
Jo HandelsmanDepartment of Molecular, Cellular and Development Biology, Yale University, New Haven, CT, United States of America.
Paulette CharlierInBioS, Centre d'Ingénierie des Protéines, Université de Liège, Liège, Belgium.
Gabriel GutkindCátedra de Microbiología, Departamento de Microbiología, Inmunología y Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Eric SauvageInBioS, Centre d'Ingénierie des Protéines, Université de Liège, Liège, Belgium.
Pablo PowerCátedra de Microbiología, Departamento de Microbiología, Inmunología y Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.ORCID http://orcid.org/0000-0002-7051-9954
University of Liège · BEConsejo Nacional de Investigaciones Científicas y Técnicas · ARUniversidad de Buenos Aires · ARYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed the kinetic properties of the metagenomic class B3 β-lactamase LRA-12, and determined its crystallographic structure in order to compare it with prevalent metallo-β-lactamases (MBLs) associated with clinical pathogens. We showed that LRA-12 confers extended-spectrum resistance on E. coli when expressed from recombinant clones, and the MIC values for carbapenems were similar to those observed in enterobacteria expressing plasmid-borne MBLs such as VIM, IMP or NDM. This was in agreement with the strong carbapenemase activity displayed by LRA-12, similar to GOB β-lactamases. Among the chelating agents evaluated, dipicolinic acid inhibited the enzyme more strongly than EDTA, which required pre-incubation with the enzyme to achieve measurable inhibition. Structurally, LRA-12 contains the conserved main structural features of di-zinc class B β-lactamases, and presents unique structural signatures that differentiate this enzyme from others within the family: (i) two loops (α3-β7 and β11-α5) that could influence antibiotic entrance and remodeling of the active site cavity; (ii) a voluminous catalytic cavity probably responsible for the high hydrolytic efficiency of the enzyme; (iii) the absence of disulfide bridges; (iv) a unique Gln116 at metal-binding site 1; (v) a methionine residue at position 221that replaces Cys/Ser found in other B3 β-lactamases in a predominantly hydrophobic environment, likely playing a role in protein stability. The structure of LRA-12 indicates that MBLs exist in wild microbial populations in extreme environments, or environments with low anthropic impact, and under the appropriate antibiotic selective pressure could be captured and disseminated to pathogens.

Indexed as

MetagenomeSoilAlaskaAmino Acid SequenceBacterial Proteinsbeta-LactamasesBiocatalysisCatalytic DomainChelating AgentsCrystallography, X-RayDrug Resistance, BacterialEdetic AcidEscherichia coliKineticsMicrobial Sensitivity TestsModels, MolecularBacterial Proteinsbeta-LactamasescarbapenemaseChelating AgentsEdetic AcidSoilZinc

Identifiers

PMID28750094
PMCPMC5531557
OpenAlexW2739831073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.